Alligator Bioscience has renegotiated its outstanding loan from Fenja Capital II. Fenja Capital waives the requirement that 50 percent of the net proceeds from TO 13 be used for amortization. The loan's maturity date is extended to December 31, 2025. Fenja Capital can convert the loan into ordinary shares through offsetting at a price of SEK 3,74 per share. The company has received subscription intentions from the Chairman of the Board, CEO and CFO for a total of SEK 0,2 million.
|
Published September 9, 2025
Alligator Bioscience renegotiates loan with Fenja Capital
Notes
Flerie and Lipum enter into merger plan
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
NEWSLETTER
Today's news roundup
News roundup Tuesday, November 18
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account